Home > Publications Database > Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies. > print

001     137575
005     20240321220256.0
024 7 _ |a 10.1212/WNL.0000000000000470
|2 doi
024 7 _ |a pmid:24808014
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a altmetric:2335375
|2 altmetric
037 _ _ |a DZNE-2020-03897
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Szentkirályi, András
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Multimorbidity and the risk of restless legs syndrome in 2 prospective cohort studies.
260 _ _ |a [S.l.]
|c 2014
|b Ovid
264 _ 1 |3 online
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2014-05-07
264 _ 1 |3 print
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2014-06-03
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1585913191_28976
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Our aim was to evaluate the association between the cumulative effect of comorbidity and the risk of restless legs syndrome (RLS) in 2 population-based German cohort studies.The Dortmund Health Study (DHS) (n = 1,312; median follow-up time: 2.1 years) and the Study of Health in Pomerania (SHIP) (n = 4,308; median follow-up time: 5.0 years) were used for the analyses. RLS was assessed at baseline and follow-up according to the RLS minimal criteria. A comorbidity index was calculated as a sum of the following conditions: diabetes, hypertension, myocardial infarction, obesity, stroke, cancer, renal disease, anemia, depression, thyroid disease, and migraine. The relationship between comorbidity and incident RLS was analyzed with multivariate logistic regression models.An increase in the number of comorbid conditions at baseline predicted prevalent RLS (DHS: trend odds ratio [OR] = 1.24, 95% confidence interval [CI] 0.99-1.56; SHIP: trend OR = 1.34, 95% CI 1.18-1.52) and incident RLS (DHS: trend OR = 1.32, 95% CI 1.04-1.68; SHIP: trend OR = 1.59, 95% CI 1.37-1.85) after adjustment for several covariates. The ORs for incident RLS associated with 3 or more comorbid diseases (DHS: OR = 2.51, 95% CI 1.18-5.34; SHIP: OR = 4.30, 95% CI 2.60-7.11) were higher than the ORs for any single disease.Multimorbidity was a strong risk factor for RLS in these 2 population-based cohort studies. The results support the hypothesis that cumulative disease burden is more important than the presence of a specific single disease in the pathophysiology of RLS.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Comorbidity
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Germany: epidemiology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Prevalence
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Restless Legs Syndrome: epidemiology
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
700 1 _ |a Völzke, Henry
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 2
|u dzne
700 1 _ |a Trenkwalder, Claudia
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Berger, Klaus
|0 P:(DE-HGF)0
|b 4
773 1 8 |a 10.1212/wnl.0000000000000470
|b : Ovid Technologies (Wolters Kluwer Health), 2014-05-07
|n 22
|p 2026-2033
|3 journal-article
|2 Crossref
|t Neurology
|v 82
|y 2014
|x 0028-3878
773 _ _ |a 10.1212/WNL.0000000000000470
|g Vol. 82, no. 22, p. 2026 - 2033
|0 PERI:(DE-600)1491874-2
|n 22
|q 82:22<2026 - 2033
|p 2026-2033
|t Neurology
|v 82
|y 2014
|x 0028-3878
909 C O |o oai:pub.dzne.de:137575
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000040
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2014
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2017
920 1 _ |0 I:(DE-2719)1510600
|k Translational Health Care Research
|l Translational Health Care Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21